Petros Pharmaceuticals, Inc. (PTPI) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PTPI Revenue Growth
Revenue Breakdown (FY 2024)
PTPI's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
PTPI Revenue Analysis (2018–2024)
As of May 9, 2026, Petros Pharmaceuticals, Inc. (PTPI) generated trailing twelve-month (TTM) revenue of $725,403, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, PTPI's 5-year compound annual growth rate (CAGR) stands at -20.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $15.6 million in 2019.
Revenue diversification analysis shows PTPI's business is primarily driven by Medical Devices (100%). With over half of revenue concentrated in Medical Devices, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PRGO (-3.6% YoY), HIMS (+59.0% YoY), and MNKD (+21.2% YoY), PTPI has underperformed the peer group in terms of revenue growth. Compare PTPI vs PRGO →
PTPI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PTPICurrent | $725,403 | -100.0% | -20.0% | -345.8% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% | |
 MNKD | $349M | +21.2% | +39.9% | 11.1% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% |
PTPI Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $5.1M | -12.2% | $3.9M | 76.3% | $-17,679,650 | -345.8% |
| 2023 | $5.8M | -2.8% | $4.2M | 72.0% | $-13,617,364 | -233.9% |
| 2022 | $6.0M | -23.3% | $3.7M | 61.8% | $-19,915,749 | -332.4% |
| 2021 | $7.8M | -18.3% | $6.2M | 79.5% | $-18,048,016 | -231.1% |
| 2020 | $9.6M | -38.6% | $5.5M | 57.7% | $-17,282,039 | -180.8% |
| 2019 | $15.6M | +10.9% | $2.9M | 18.4% | $-19,312,205 | -124.0% |
| 2018 | $14.1M | - | $3.6M | 25.4% | $-7,650,270 | -54.4% |
See PTPI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTPI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTPI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTPI — Frequently Asked Questions
Quick answers to the most common questions about buying PTPI stock.
Is PTPI's revenue growth accelerating or slowing?
PTPI revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of -20.0%. TTM revenue fell to $725403.00. This reverses the prior growth trend.
What is PTPI's long-term revenue growth rate?
Petros Pharmaceuticals, Inc.'s 5-year revenue CAGR of -20.0% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is PTPI's revenue distributed by segment?
PTPI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.